Emerging Biomarkers in Canine Glaucoma: Insights into Clinical, Genetic, Oxidative, and Inflammatory Pathways

This is the authors' abstract. We don't add key points for this paper.

Canine glaucoma is a complex ocular disorder characterized by the progressive loss of retinal ganglion cells (RGCs) and specific optic nerve damage, often resulting in permanent blindness in affected dogs. Recent advancements emphasize the importance of various biomarkers in understanding the development and progression of canine glaucoma, especially concerning clinical signs, genetics, oxidative stress, and inflammation pathways. An imbalance between the production and drainage of aqueous humor significantly impacts intraocular pressure (IOP), a key factor in managing glaucoma. Oxidative stress has emerged as a key contributor to RGC degeneration in canine glaucoma, mirroring findings in human studies, where it is implicated in glaucomatous neurodegeneration. The interaction between oxidative stress and pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) in the aqueous humor reflects a complex biomarker network with potential diagnostic and therapeutic value. The identification of genetic biomarkers, including enzyme and protein variants, also indicates a move toward molecular methods for evaluating glaucoma risk across different dog breeds. Understanding these interconnected factors offers valuable insights into novel treatments and preventative measures, including genetic screening, oxidative stress monitoring, employing anti-inflammatory, and neuroprotective therapies. Continued biomarker research is essential for improving clinical outcomes in canine glaucoma and may also offer translational relevance to human glaucomatous diseases, thereby broadening future therapeutic possibilities.